+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Apoptotic and proliferative index after alpha-blocker and/or finasteride treatment in benign prostatic hyperplasia



Apoptotic and proliferative index after alpha-blocker and/or finasteride treatment in benign prostatic hyperplasia



Journal of Urology 165(5 Suppl.): 213




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034429749

Download citation: RISBibTeXText


Related references

Apoptotic and proliferative index after Alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia. Urologia Internationalis 69(4): 287-292, 2002

Apoptotic and Proliferative Index after Alpha-1-Adrenoceptor Antagonist and/or Finasteride Treatment in Benign Prostatic Hyperplasia. Urologia Internationalis 69(4): 287-292, 2002

Effect of finasteride and terazosin on apoptotic and proliferative indices in benign prostatic hyperplasia. Journal of Urology 161(4 Suppl. ): 226, 1999

Comparison of Characteristics of Benign Prostatic Hyperplasia (BPH) Patients Treated with Finasteride and Alpha Blocker Combination Therapy Versus Alpha Blocker Monotherapy in China: An Analysis of Electronic Medical Record Data. Advances in Therapy 35(8): 1191-1198, 2018

Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States. Journal of Managed Care and Specialty Pharmacy 22(10): 1204-1214, 2016

Finasteride: The first 5-alpha-reductase inhibitor in the treatment of benign prostatic hyperplasia. Farmacia Clinica 10(9): 749-750,752-754,756-757, 1993

The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group. Journal of Urology 147(5): 1298-1302, 1992

Longterm treatment of benign prostatic hyperplasia with the 5 alpha reductase inhibitor finasteride mk 906. Journal of Urology 145(4 Suppl.): 265A, 1991

α-blocker monotherapy and α-blocker plus 5-alpha-reductase inhibitor combination treatment in benign prostatic hyperplasia; 10 years' long-term results. Korean Journal of Urology 53(4): 248-252, 2012

One-year experience in the treatment of benign prostatic hyperplasia with finasteride. The MK-906 (Finasteride) Study Group. Journal of Andrology 12(6): 372-375, 1991

Efficacy of alpha blocker treatment according to the degree of intravesical prostatic protrusion detected by transrectal ultrasonography in patients with benign prostatic hyperplasia. Korean Journal of Urology 53(2): 92-97, 2012

Study of the association between ischemic heart disease and use of alpha-blockers and finasteride indicated for the treatment of benign prostatic hyperplasia. European Urology 42(3): 254-261, 2002

Finasteride for the treatment and control of benign prostatic hyperplasia: summary of phase III controlled studies. The Finasteride Study Group. European Urology 25(Suppl. 1): 24-28, 1994

Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. Journal of Clinical Endocrinology and Metabolism 74(3): 505-508, 1992

Treatment patterns in alpha-blocker therapy for benign prostatic hyperplasia. American Journal of Men's Health 8(3): 267-272, 2014